CDK2 and cancer: In this regard, the conjugated compounds XVI, XVII, and XVIII are examples of s-triazine analogs that have shown significant inhibitory activity against CDK-2 and therefore significant activity against a wide spectrum of cancer cell lines (Kumar et al., 2019).